References
Lacki JK. Management of the patient with severe refractory rheumatoid arthritis. Are the newer treatment options worth considering? Biodrugs 2000 Jun; 13(6): 425–35
Prakash A, Jarvis B. Leflumomide. A review of its use in active rheumatoid arthritis. Drugs 1999 Dec; 58(6): 1137–64
Jarvis B, Faulds D. Etanercept. A review of its use in rheumatoid arthritis. Drugs 1999 Jun; 57(6): 945–66
Markham A, Lamb HM. Infliximab. A review of its use in the management of rheumatoid arthritis. Drugs 2000 Jun; 59(6): 1341–59
McQueen FM, Stewart N, Crabbe J, et al. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosion at four months after symptom onset. Ann Rheum Dis 1998; 57: 350–6
van der Heijde DMFM. Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol 1995; 34 Suppl.2: 59–73
Pincus T. Clinical observations often provide more accurate information concerning the long-term natural history and results than structured research studies. Rheumatol Eur 1995; 2 Suppl.: 179–84
Pincus T, O’Dell JR, Kremer JM. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventative strategy. Ann Intern Med 1999 Nov 16; 131: 768–74
Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1995; 38: 727–35
American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996: 39: 713–22
PDR 55th ed. Montvale NJ: Medical Economics, 2001 pp. 685-9, 828-9, 1085-88, 1551-54 and PDR 53rd ed. 1999 pp. 1397-1401
Arava: steps taken after granting marketing authorisation [online]. European Agency for the Evaluation of Medicinal Products. May 2001. Available from: URL: http://www.eudra.org/humandocs/Humans/EPAR/Arava/Arava.htm
Smolen JS, Steiner G, Breedveld FC, et al. Anti-TNFα therapy and drug induced lupus-like syndrome [abstract no. 906]. Ann Rheum Dis 1999 Jun 6; EULAR Suppl.: 217
Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of Etanercept, a recombinant tumor necrosis factor receptor. Fcfusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999 Jan 28; 340: 253–9
Maini R, St Clair EW, Breedveld FC, et al. Infliximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999 Dec 4; 354: 1923–9
Centocor Inc. X-ray study suggests Remicade™ stops progression of rheumatoid arthritis [media release]; 15 Nov 1999 [3 pages]
Rights and permissions
About this article
Cite this article
Treatment options for patients with severe rheumatoid arthritis are gradually increasing. Drugs Ther. Perspect 17, 4–8 (2001). https://doi.org/10.2165/00042310-200117120-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-200117120-00002